Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Sham-Controlled Trial of Low Intensity Focused Ultrasound Neuromodulation as an Adjunctive Treatment for Gambling Disorder

NCT07923032 is registered in ClinicalTrials.gov with University of Virginia as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07923032 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Sham-Controlled Trial of Low Intensity Focused Ultrasound Neuromodulation as an Adjunctive Treatment for Gambling Disorder
Lead sponsor
University of Virginia
Phase
Not applicable
Overall status
Not yet recruiting
Start date
February 28, 2027
Completion date
June 30, 2029
Enrollment
54 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gambling, gambling addiction, gambling disorder, gambling problem

Arms

As registered; 2 arms.

  • Active LIFU Treatment ExperimentalActive Low-Intensity Focused Ultrasound (LIFU)

    Device: Low Intensity Focused Ultrasound

    * Each course comprises of three 10-minute sessions of Active LIFU per day (5 minutes to the left NAc, then 5 minutes to the right) on three treatment days scheduled within a 5-day window (i.e., nine sessions per course).
    * During the randomized phase (through post-LIFU Day 30), the trial operates as a parallel-group comparison of active LIFU versus sham, with both arms receiving standard-of-care, once-weekly telehealth CBT.

  • Sham LIFU Treatment Sham comparatorSham Low-Intensity Focused Ultrasound (LIFU)

    Device: Low Intensity Focused Ultrasound

    * Each course comprises of three 10-minute sessions of Sham LIFU per day (5 minutes to the left NAc, then 5 minutes to the right) on three treatment days scheduled within a 5-day window (i.e., nine sessions per course).
    * Sham session is procedurally identical to Active LIFU session with the exception that no energy is delivered during the procedures.
    * During the randomized phase (through post-LIFU Day 30), the trial operates as a parallel-group comparison of active LIFU versus sham, with both arms receiving standard-of-care once-weekly telehealth CBT.
    * After the Day 30 primary endpoint and unblinding, the sham arm crosses over to open-label active LIFU and repeats the identical treatment and assessment sequence, so every participant ultimately receives active treatment.

Primary endpoints

Registered primary outcome measures; 2 primary.

  • Incidence of Device-Related and Procedure-Related Adverse Events Randomization through Day 30

    Number of participants who experience at least one device-related or investigational procedure-related adverse event (AE) or serious adverse event (SAE) during the randomized treatment phase. Adverse event severity and relationship to study procedures will be assessed by the study investigator.

  • Change From Baseline in Gambling Frequency Measured by the Gambling Timeline Follow-Back (G-TLFB) Baseline to Day 30

    The G-TLFB is a calendar-based self-report assessment that uses memory cues and a timeline method to estimate gambling activity over a specified period. Gambling frequency is assessed by retrospectively recording gambling behavior during the assessment period. Higher values indicate greater gambling frequency.

Lead sponsor's other trials

University of Virginia, most recent start first.

Similar trials

Same condition (Gambling) and phase, most recent start first.